IMMUCOR INC
			Symbol			BLUD

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

The Pomerantz Firm Charges Immucor, Inc. With Securities Fraud -- BLUD

2009-10-02 09:18 ET - News Release

NEW YORK, Oct. 2, 2009 (GLOBE NEWSWIRE) -- Pomerantz Haudek Grossman & Gross LLP (www.pomerantzlaw.com) ("Pomerantz") has filed a class action lawsuit in the United States District Court, Northern District of Georgia, against Immucor, Inc. ("Immucor" or the "Company") (Nasdaq:BLUD) and certain of its top officials. The class action (09-CV-2714) was filed on behalf of purchasers of the securities of the Company between October 19, 2005 and April 23, 2009 inclusive, (the "Class Period"). The Complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5 promulgated thereunder.

Immucor develops, manufactures, and sells a line of blood reagents and automated systems used primarily by hospitals, clinical laboratories, and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. The Complaint alleges that throughout the Class Period defendants materially misrepresented the Company's business operations by failing to disclose that the Company was operating in violation of federal antitrust laws. Specifically, the Complaint alleges the defendants made false or misleading statements and failed to disclose: (1) that the Company had engaged in unlawful business practices with its competitors; (2) that the Company had agreed with its competitors in the industry to fix, raise, maintain, and stabilize prices for blood reagents and related medical equipment in the U.S. market; (3) that the Company's revenues had been significantly increased through the employment of such unlawful business practices; (4) that, as a result, the Company's financial statements were false and misleading at all relevant times; (5) that such unlawful business practices, when they were discovered, would initiate an investigation by the government into the Company's business practices; (6) that the Company lacked adequate internal and financial controls; and (7) that, as a result of the foregoing, the Company's statements about its financial well-being and future business prospects were lacking in any reasonable bases when made.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.